 |
drug-information.ru |
|Plasma-Lyte 148 and Dextrose Plasma-Lyte 56 |
| Drugs search, click the first letter of a drug name: | A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 1 | 2 | 3 | 4 | 5 | 6 | 8 | 9 Home Plasma-Lyte 148 and DextroseGeneric Name: Multiple Electrolytes and Dextrose Injection, Type 1, USP Dosage Form: Injection Plasma-Lyte 148 and Dextrose DescriptionPlasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is a sterile, nonpyrogenic solution for fluid and electrolyte replenishment and caloric supply in a single dose container for intravenous administration. Each 100 mL contains 5 g Dextrose Hydrous, USP*, 526 mg Sodium Chloride, USP (NaCl); 502 mg Sodium Gluconate (C6H11NaO7); 368 mg Sodium Acetate Trihydrate, USP (C2H3NaO2•3H2O), 37 mg Potassium Chloride, USP (KCl); and 30 mg Magnesium Chloride, USP (MgCl2•6H2O). It contains no antimicrobial agents. The pH is 5.0 (4.0 to 6.5). The pH is adjusted with hydrochloric acid.  Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) administered intravenously has value as a source of water, electrolytes, and calories. One liter has an ionic concentration of 140 mEq sodium, 5 mEq potassium, 3 mEq magnesium, 98 mEq chloride, 27 mEq acetate and 23 mEq gluconate. The osmolarity is 547 mOsmol/L (calc). Normal physiologic osmolarity range is approximately 280 to 310 mOsmol/L. Administration of substantially hypertonic solutions (≥ 600 mOsmol/L) may cause vein damage. The caloric content is 190 kcal/L. The Viaflex® plastic container is fabricated from a specially formulated polyvinyl chloride (PL 146® Plastic). The amount of water that can permeate from inside the container into the overwrap is insufficient to affect the solution significantly. Solutions in contact with the plastic container may leach out certain chemical components from the plastic in very small amounts; however, biological testing was supportive of the safety of the plastic container materials. Plasma-Lyte 148 and Dextrose - Clinical PharmacologyPlasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) has value as a source of water, electrolytes, and calories. It is capable of inducing diuresis depending on the clinical condition of the patient. Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) produces a metabolic alkalinizing effect. Acetate and gluconate ions are metabolized ultimately to carbon dioxide and water, which requires the consumption of hydrogen cations. Indications and Usage for Plasma-Lyte 148 and DextrosePlasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is indicated as a source of water, electrolytes, and calories, or as an alkalinizing agent. ContraindicationsSolutions containing dextrose may be contraindicated in patients with known allergy to corn or corn products. WarningsPlasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care, if at all, in patients with congestive heart failure, severe renal insufficiency and in clinical states in which there exists edema with sodium retention. Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care, if at all, in patients with hyperkalemia, severe renal failure and in conditions in which potassium retention is present. Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with great care in patients with metabolic or respiratory alkalosis. The administration of acetate or gluconate ions should be done with great care in those conditions in which there is an increased level or an impaired utilization of these ions, such as severe hepatic insufficiency. The intravenous administration of Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fluid and/or solute overloading resulting in dilution of serum electrolyte concentrations, overhydration, congested states, or pulmonary edema. The risk of dilutional states is inversely proportional to the electrolyte concentrations of the injection. The risk of solute overload causing congested states with peripheral and pulmonary edema is directly proportional to the electrolyte concentrations of the injection. In patients with diminished renal function, administration of Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) may result in sodium or potassium retention. GENERAL PRECAUTIONSClinical evaluation and periodic laboratory determinations are necessary to monitor changes in fluid balance, electrolyte concentrations and acid base balance during prolonged parenteral therapy or whenever the condition of the patient warrants such evaluation. Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution. Excess administration may result in metabolic alkalosis. Caution must be exercised in the administration of Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) to patients receiving corticosteroids or corticotropin. Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be used with caution in patients with overt or subclinical diabetes mellitus. PregnancyTeratogenic EffectsPregnancy Category CAnimal reproduction studies have not been conducted with Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP). It is also not known whether Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) should be given to a pregnant woman only if clearly needed. Pediatric UseSafety and effectiveness of Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in pediatric patients have not been established by adequate and well controlled trials, however, the use of plasmalyte and dextrose solutions in the pediatric population is referenced in the medical literature. The warnings, precautions and adverse reactions identified in the label copy should be observed in the pediatric population. In very low birth weight infants, excessive or rapid administration of dextrose injection may result in increased serum osmolality and possible hemorrhage. Carcinogenesis and Mutagenesis and Impairment of FertilityStudies with Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) have not been performed to evaluate carcinogenic potential, mutagenic potential, or effects on fertility. Nursing MothersIt is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) is administered to a nursing mother. Geriatric UseClinical studies of Plasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or drug therapy. Do not administer unless solution is clear and seal is intact. Adverse ReactionsReactions which may occur because of the solution or the technique of administration include febrile response, infection at the site of injection, venous thrombosis or phlebitis extending from the site of injection, extravasation and hypervolemia. If an adverse reaction does occur, discontinue the infusion, evaluate the patient, institute appropriate therapeutic countermeasures, and save the remainder of the fluid for examination if deemed necessary. Plasma-Lyte 148 and Dextrose Dosage and AdministrationAs directed by a physician. Dosage is dependent upon the age, weight and clinical condition of the patient as well as laboratory determinations. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration whenever solution and container permit. All injections in Viaflex® plastic containers are intended for intravenous administration using sterile equipment. As reported in the literature, the dosage and constant infusion rate of intravenous dextrose must be selected with caution in pediatric patients, particularly neonates and low weight infants, because of the increased risk of hyperglycemia/hypoglycemia. Additives may be incompatible. Complete information is not available. Those additives known to be incompatible should not be used. Consult with pharmacist, if available. If, in the informed judgment of the physician, it is deemed advisable to introduce additives, use aseptic technique. Mix thoroughly when additives have been introduced. Do not store solutions containing additives. How is Plasma-Lyte 148 and Dextrose SuppliedPlasma-Lyte® 148 and 5% Dextrose Injection (Multiple Electrolytes and Dextrose Injection, Type 1, USP) in Viaflex® plastic containers is available as shown below:
Exposure of pharmaceutical products to heat should be minimized. Avoid excessive heat. It is recommended the product be stored at room temperature (25°C); brief exposure up to 40°C does not adversely affect the product. DIRECTIONS FOR USE OF VIAFLEX® PLASTIC CONTAINERWarning: Do not use plastic containers in series connections. Such use could result in air embolism due to residual air being drawn from the primary container before administration of the fluid from the secondary container is completed. To OpenTear overwrap down side at slit and remove solution container. Some opacity of the plastic due to moisture absorption during the sterilization process may be observed. This is normal and does not affect the solution quality or safety. The opacity will diminish gradually. Check for minute leaks by squeezing inner bag firmly. If leaks are found, discard solution as sterility may be impaired. If supplemental medication is desired, follow directions below. Preparation for Administration1. Suspend container from eyelet support. 2. Remove plastic protector from outlet port at bottom of container. 3. Attach administration set. Refer to complete directions accompanying set. To Add MedicationWarning:Additives may be incompatible. To add medication before solution administration1. Prepare medication site. 2. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. 3. Mix solution and medication thoroughly. For high density medication such as potassium chloride, squeeze ports while ports are upright and mix thoroughly. To add medication during solution administration1. Close clamp on the set. 2. Prepare medication site. 3. Using syringe with 19 to 22 gauge needle, puncture resealable medication port and inject. 4. Remove container from IV pole and/or turn to an upright position. 5. Evacuate both ports by squeezing them while container is in the upright position. 6. Mix solution and medication thoroughly. 7. Return container to in use position and continue administration. Baxter Healthcare Corporation Deerfield, IL 60015 USA Printed in USA ©Copyright 1982, 1983, 1989, 1993, Baxter Healthcare Corporation. All rights reserved. 7-19-22-968
Revised: 04/2006 Where can I get more information about Plasma-Lyte 148 and Dextrose Plasma-Lyte 56 ? We recommend to use www.Drugs.com Typical mistypes for Plasma-Lyte 148 and Dextrose Plasma-Lyte 56 olasma-lyte 148 and dextrose plasma-lyte 56, llasma-lyte 148 and dextrose plasma-lyte 56, -lasma-lyte 148 and dextrose plasma-lyte 56, 0lasma-lyte 148 and dextrose plasma-lyte 56, pkasma-lyte 148 and dextrose plasma-lyte 56, ppasma-lyte 148 and dextrose plasma-lyte 56, poasma-lyte 148 and dextrose plasma-lyte 56, plzsma-lyte 148 and dextrose plasma-lyte 56, plssma-lyte 148 and dextrose plasma-lyte 56, plwsma-lyte 148 and dextrose plasma-lyte 56, plqsma-lyte 148 and dextrose plasma-lyte 56, plaama-lyte 148 and dextrose plasma-lyte 56, plazma-lyte 148 and dextrose plasma-lyte 56, plaxma-lyte 148 and dextrose plasma-lyte 56, pladma-lyte 148 and dextrose plasma-lyte 56, plaema-lyte 148 and dextrose plasma-lyte 56, plawma-lyte 148 and dextrose plasma-lyte 56, plasna-lyte 148 and dextrose plasma-lyte 56, plaska-lyte 148 and dextrose plasma-lyte 56, plasja-lyte 148 and dextrose plasma-lyte 56, plasmz-lyte 148 and dextrose plasma-lyte 56, plasms-lyte 148 and dextrose plasma-lyte 56, plasmw-lyte 148 and dextrose plasma-lyte 56, plasmq-lyte 148 and dextrose plasma-lyte 56, plasma0lyte 148 and dextrose plasma-lyte 56, plasmaplyte 148 and dextrose plasma-lyte 56, plasma-kyte 148 and dextrose plasma-lyte 56, plasma-pyte 148 and dextrose plasma-lyte 56, plasma-oyte 148 and dextrose plasma-lyte 56, plasma-ltte 148 and dextrose plasma-lyte 56, plasma-lgte 148 and dextrose plasma-lyte 56, plasma-lhte 148 and dextrose plasma-lyte 56, plasma-lute 148 and dextrose plasma-lyte 56, plasma-l7te 148 and dextrose plasma-lyte 56, plasma-l6te 148 and dextrose plasma-lyte 56, plasma-lyre 148 and dextrose plasma-lyte 56, plasma-lyfe 148 and dextrose plasma-lyte 56, plasma-lyge 148 and dextrose plasma-lyte 56, plasma-lyye 148 and dextrose plasma-lyte 56, plasma-ly6e 148 and dextrose plasma-lyte 56, plasma-ly5e 148 and dextrose plasma-lyte 56, plasma-lytw 148 and dextrose plasma-lyte 56, plasma-lyts 148 and dextrose plasma-lyte 56, plasma-lytd 148 and dextrose plasma-lyte 56, plasma-lytr 148 and dextrose plasma-lyte 56, plasma-lyt4 148 and dextrose plasma-lyte 56, plasma-lyt3 148 and dextrose plasma-lyte 56, plasma-lyte 248 and dextrose plasma-lyte 56, plasma-lyte q48 and dextrose plasma-lyte 56, plasma-lyte 138 and dextrose plasma-lyte 56, plasma-lyte 1e8 and dextrose plasma-lyte 56, plasma-lyte 1r8 and dextrose plasma-lyte 56, plasma-lyte 158 and dextrose plasma-lyte 56, plasma-lyte 147 and dextrose plasma-lyte 56, plasma-lyte 14u and dextrose plasma-lyte 56, plasma-lyte 14i and dextrose plasma-lyte 56, plasma-lyte 149 and dextrose plasma-lyte 56, plasma-lyte 148 znd dextrose plasma-lyte 56, plasma-lyte 148 snd dextrose plasma-lyte 56, plasma-lyte 148 wnd dextrose plasma-lyte 56, plasma-lyte 148 qnd dextrose plasma-lyte 56, plasma-lyte 148 abd dextrose plasma-lyte 56, plasma-lyte 148 amd dextrose plasma-lyte 56, plasma-lyte 148 ajd dextrose plasma-lyte 56, plasma-lyte 148 ahd dextrose plasma-lyte 56, plasma-lyte 148 ans dextrose plasma-lyte 56, plasma-lyte 148 anx dextrose plasma-lyte 56, plasma-lyte 148 anc dextrose plasma-lyte 56, plasma-lyte 148 anf dextrose plasma-lyte 56, plasma-lyte 148 anr dextrose plasma-lyte 56, plasma-lyte 148 ane dextrose plasma-lyte 56, plasma-lyte 148 and sextrose plasma-lyte 56, plasma-lyte 148 and xextrose plasma-lyte 56, plasma-lyte 148 and cextrose plasma-lyte 56, plasma-lyte 148 and fextrose plasma-lyte 56, plasma-lyte 148 and rextrose plasma-lyte 56, plasma-lyte 148 and eextrose plasma-lyte 56, plasma-lyte 148 and dwxtrose plasma-lyte 56, plasma-lyte 148 and dsxtrose plasma-lyte 56, plasma-lyte 148 and ddxtrose plasma-lyte 56, plasma-lyte 148 and drxtrose plasma-lyte 56, plasma-lyte 148 and d4xtrose plasma-lyte 56, plasma-lyte 148 and d3xtrose plasma-lyte 56, plasma-lyte 148 and deztrose plasma-lyte 56, plasma-lyte 148 and dectrose plasma-lyte 56, plasma-lyte 148 and dedtrose plasma-lyte 56, plasma-lyte 148 and destrose plasma-lyte 56, plasma-lyte 148 and dexrrose plasma-lyte 56, plasma-lyte 148 and dexfrose plasma-lyte 56, plasma-lyte 148 and dexgrose plasma-lyte 56, plasma-lyte 148 and dexyrose plasma-lyte 56, plasma-lyte 148 and dex6rose plasma-lyte 56, plasma-lyte 148 and dex5rose plasma-lyte 56, plasma-lyte 148 and dexteose plasma-lyte 56, plasma-lyte 148 and dextdose plasma-lyte 56, plasma-lyte 148 and dextfose plasma-lyte 56, plasma-lyte 148 and dexttose plasma-lyte 56, plasma-lyte 148 and dext5ose plasma-lyte 56, plasma-lyte 148 and dext4ose plasma-lyte 56, plasma-lyte 148 and dextrise plasma-lyte 56, plasma-lyte 148 and dextrkse plasma-lyte 56, plasma-lyte 148 and dextrlse plasma-lyte 56, plasma-lyte 148 and dextrpse plasma-lyte 56, plasma-lyte 148 and dextr0se plasma-lyte 56, plasma-lyte 148 and dextr9se plasma-lyte 56, plasma-lyte 148 and dextroae plasma-lyte 56, plasma-lyte 148 and dextroze plasma-lyte 56, plasma-lyte 148 and dextroxe plasma-lyte 56, plasma-lyte 148 and dextrode plasma-lyte 56, plasma-lyte 148 and dextroee plasma-lyte 56, plasma-lyte 148 and dextrowe plasma-lyte 56, plasma-lyte 148 and dextrosw plasma-lyte 56, plasma-lyte 148 and dextross plasma-lyte 56, plasma-lyte 148 and dextrosd plasma-lyte 56, plasma-lyte 148 and dextrosr plasma-lyte 56, plasma-lyte 148 and dextros4 plasma-lyte 56, plasma-lyte 148 and dextros3 plasma-lyte 56, plasma-lyte 148 and dextrose olasma-lyte 56, plasma-lyte 148 and dextrose llasma-lyte 56, plasma-lyte 148 and dextrose -lasma-lyte 56, plasma-lyte 148 and dextrose 0lasma-lyte 56, plasma-lyte 148 and dextrose pkasma-lyte 56, plasma-lyte 148 and dextrose ppasma-lyte 56, plasma-lyte 148 and dextrose poasma-lyte 56, plasma-lyte 148 and dextrose plzsma-lyte 56, plasma-lyte 148 and dextrose plssma-lyte 56, plasma-lyte 148 and dextrose plwsma-lyte 56, plasma-lyte 148 and dextrose plqsma-lyte 56, plasma-lyte 148 and dextrose plaama-lyte 56, plasma-lyte 148 and dextrose plazma-lyte 56, plasma-lyte 148 and dextrose plaxma-lyte 56, plasma-lyte 148 and dextrose pladma-lyte 56, plasma-lyte 148 and dextrose plaema-lyte 56, plasma-lyte 148 and dextrose plawma-lyte 56, plasma-lyte 148 and dextrose plasna-lyte 56, plasma-lyte 148 and dextrose plaska-lyte 56, plasma-lyte 148 and dextrose plasja-lyte 56, plasma-lyte 148 and dextrose plasmz-lyte 56, plasma-lyte 148 and dextrose plasms-lyte 56, plasma-lyte 148 and dextrose plasmw-lyte 56, plasma-lyte 148 and dextrose plasmq-lyte 56, plasma-lyte 148 and dextrose plasma0lyte 56, plasma-lyte 148 and dextrose plasmaplyte 56, plasma-lyte 148 and dextrose plasma-kyte 56, plasma-lyte 148 and dextrose plasma-pyte 56, plasma-lyte 148 and dextrose plasma-oyte 56, plasma-lyte 148 and dextrose plasma-ltte 56, plasma-lyte 148 and dextrose plasma-lgte 56, plasma-lyte 148 and dextrose plasma-lhte 56, plasma-lyte 148 and dextrose plasma-lute 56, plasma-lyte 148 and dextrose plasma-l7te 56, plasma-lyte 148 and dextrose plasma-l6te 56, plasma-lyte 148 and dextrose plasma-lyre 56, plasma-lyte 148 and dextrose plasma-lyfe 56, plasma-lyte 148 and dextrose plasma-lyge 56, plasma-lyte 148 and dextrose plasma-lyye 56, plasma-lyte 148 and dextrose plasma-ly6e 56, plasma-lyte 148 and dextrose plasma-ly5e 56, plasma-lyte 148 and dextrose plasma-lytw 56, plasma-lyte 148 and dextrose plasma-lyts 56, plasma-lyte 148 and dextrose plasma-lytd 56, plasma-lyte 148 and dextrose plasma-lytr 56, plasma-lyte 148 and dextrose plasma-lyt4 56, plasma-lyte 148 and dextrose plasma-lyt3 56, plasma-lyte 148 and dextrose plasma-lyte 46, plasma-lyte 148 and dextrose plasma-lyte r6, plasma-lyte 148 and dextrose plasma-lyte t6, plasma-lyte 148 and dextrose plasma-lyte 66, plasma-lyte 148 and dextrose plasma-lyte 55, plasma-lyte 148 and dextrose plasma-lyte 5t, plasma-lyte 148 and dextrose plasma-lyte 5y, plasma-lyte 148 and dextrose plasma-lyte 57, lasma-lyte 148 and dextrose plasma-lyte 56, pasma-lyte 148 and dextrose plasma-lyte 56, plsma-lyte 148 and dextrose plasma-lyte 56, plama-lyte 148 and dextrose plasma-lyte 56, plasa-lyte 148 and dextrose plasma-lyte 56, plasm-lyte 148 and dextrose plasma-lyte 56, plasmalyte 148 and dextrose plasma-lyte 56, plasma-yte 148 and dextrose plasma-lyte 56, plasma-lte 148 and dextrose plasma-lyte 56, plasma-lye 148 and dextrose plasma-lyte 56, plasma-lyt 148 and dextrose plasma-lyte 56, plasma-lyte148 and dextrose plasma-lyte 56, plasma-lyte 48 and dextrose plasma-lyte 56, plasma-lyte 18 and dextrose plasma-lyte 56, plasma-lyte 14 and dextrose plasma-lyte 56, plasma-lyte 148and dextrose plasma-lyte 56, plasma-lyte 148 nd dextrose plasma-lyte 56, plasma-lyte 148 ad dextrose plasma-lyte 56, plasma-lyte 148 an dextrose plasma-lyte 56, plasma-lyte 148 anddextrose plasma-lyte 56, plasma-lyte 148 and extrose plasma-lyte 56, plasma-lyte 148 and dxtrose plasma-lyte 56, plasma-lyte 148 and detrose plasma-lyte 56, plasma-lyte 148 and dexrose plasma-lyte 56, plasma-lyte 148 and dextose plasma-lyte 56, plasma-lyte 148 and dextrse plasma-lyte 56, plasma-lyte 148 and dextroe plasma-lyte 56, plasma-lyte 148 and dextros plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose lasma-lyte 56, plasma-lyte 148 and dextrose pasma-lyte 56, plasma-lyte 148 and dextrose plsma-lyte 56, plasma-lyte 148 and dextrose plama-lyte 56, plasma-lyte 148 and dextrose plasa-lyte 56, plasma-lyte 148 and dextrose plasm-lyte 56, plasma-lyte 148 and dextrose plasmalyte 56, plasma-lyte 148 and dextrose plasma-yte 56, plasma-lyte 148 and dextrose plasma-lte 56, plasma-lyte 148 and dextrose plasma-lye 56, plasma-lyte 148 and dextrose plasma-lyt 56, plasma-lyte 148 and dextrose plasma-lyte56, plasma-lyte 148 and dextrose plasma-lyte 6, plasma-lyte 148 and dextrose plasma-lyte 5, lpasma-lyte 148 and dextrose plasma-lyte 56, palsma-lyte 148 and dextrose plasma-lyte 56, plsama-lyte 148 and dextrose plasma-lyte 56, plamsa-lyte 148 and dextrose plasma-lyte 56, plasam-lyte 148 and dextrose plasma-lyte 56, plasm-alyte 148 and dextrose plasma-lyte 56, plasmal-yte 148 and dextrose plasma-lyte 56, plasma-ylte 148 and dextrose plasma-lyte 56, plasma-ltye 148 and dextrose plasma-lyte 56, plasma-lyet 148 and dextrose plasma-lyte 56, plasma-lyt e148 and dextrose plasma-lyte 56, plasma-lyte1 48 and dextrose plasma-lyte 56, plasma-lyte 418 and dextrose plasma-lyte 56, plasma-lyte 184 and dextrose plasma-lyte 56, plasma-lyte 14 8and dextrose plasma-lyte 56, plasma-lyte 148a nd dextrose plasma-lyte 56, plasma-lyte 148 nad dextrose plasma-lyte 56, plasma-lyte 148 adn dextrose plasma-lyte 56, plasma-lyte 148 an ddextrose plasma-lyte 56, plasma-lyte 148 andd extrose plasma-lyte 56, plasma-lyte 148 and edxtrose plasma-lyte 56, plasma-lyte 148 and dxetrose plasma-lyte 56, plasma-lyte 148 and detxrose plasma-lyte 56, plasma-lyte 148 and dexrtose plasma-lyte 56, plasma-lyte 148 and dextorse plasma-lyte 56, plasma-lyte 148 and dextrsoe plasma-lyte 56, plasma-lyte 148 and dextroes plasma-lyte 56, plasma-lyte 148 and dextros e plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose p lasma-lyte 56, plasma-lyte 148 and dextrose lpasma-lyte 56, plasma-lyte 148 and dextrose palsma-lyte 56, plasma-lyte 148 and dextrose plsama-lyte 56, plasma-lyte 148 and dextrose plamsa-lyte 56, plasma-lyte 148 and dextrose plasam-lyte 56, plasma-lyte 148 and dextrose plasm-alyte 56, plasma-lyte 148 and dextrose plasmal-yte 56, plasma-lyte 148 and dextrose plasma-ylte 56, plasma-lyte 148 and dextrose plasma-ltye 56, plasma-lyte 148 and dextrose plasma-lyet 56, plasma-lyte 148 and dextrose plasma-lyt e56, plasma-lyte 148 and dextrose plasma-lyte5 6, plasma-lyte 148 and dextrose plasma-lyte 65, pplasma-lyte 148 and dextrose plasma-lyte 56, pllasma-lyte 148 and dextrose plasma-lyte 56, plaasma-lyte 148 and dextrose plasma-lyte 56, plassma-lyte 148 and dextrose plasma-lyte 56, plasmma-lyte 148 and dextrose plasma-lyte 56, plasmaa-lyte 148 and dextrose plasma-lyte 56, plasma--lyte 148 and dextrose plasma-lyte 56, plasma-llyte 148 and dextrose plasma-lyte 56, plasma-lyyte 148 and dextrose plasma-lyte 56, plasma-lytte 148 and dextrose plasma-lyte 56, plasma-lytee 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 1148 and dextrose plasma-lyte 56, plasma-lyte 1448 and dextrose plasma-lyte 56, plasma-lyte 1488 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 aand dextrose plasma-lyte 56, plasma-lyte 148 annd dextrose plasma-lyte 56, plasma-lyte 148 andd dextrose plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and ddextrose plasma-lyte 56, plasma-lyte 148 and deextrose plasma-lyte 56, plasma-lyte 148 and dexxtrose plasma-lyte 56, plasma-lyte 148 and dexttrose plasma-lyte 56, plasma-lyte 148 and dextrrose plasma-lyte 56, plasma-lyte 148 and dextroose plasma-lyte 56, plasma-lyte 148 and dextrosse plasma-lyte 56, plasma-lyte 148 and dextrosee plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose pplasma-lyte 56, plasma-lyte 148 and dextrose pllasma-lyte 56, plasma-lyte 148 and dextrose plaasma-lyte 56, plasma-lyte 148 and dextrose plassma-lyte 56, plasma-lyte 148 and dextrose plasmma-lyte 56, plasma-lyte 148 and dextrose plasmaa-lyte 56, plasma-lyte 148 and dextrose plasma--lyte 56, plasma-lyte 148 and dextrose plasma-llyte 56, plasma-lyte 148 and dextrose plasma-lyyte 56, plasma-lyte 148 and dextrose plasma-lytte 56, plasma-lyte 148 and dextrose plasma-lytee 56, plasma-lyte 148 and dextrose plasma-lyte 56, plasma-lyte 148 and dextrose plasma-lyte 556, plasma-lyte 148 and dextrose plasma-lyte 566, etc.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||